HIV Research Highlights from First Day of CROI 2018

Date: 03/06/2018

Publication:

NIH/NIAID Website

. . . Short-course regimen for TB prevention—A one-month antibiotic regimen to prevent active tuberculosis (TB) disease was at least as safe and effective as the standard nine-month therapy for people living with HIV, according to the results of a large international clinical trial. These findings could be a “game changer” for helping people stay TB-free, remarked Dr. Dieffenbach, noting that TB is the single biggest killer of HIV+ people around the globe. Adults and adolescents in the trial were more likely to complete the short-course regimen—consisting of daily doses of the antibiotics rifapentine and isoniazid for four weeks—than the standard nine-month regimen of daily isoniazid, according to the findings presented by Richard Chaisson, MD, of Johns Hopkins. The study was sponsored by NIAID and conducted by the NIAID-funded AIDS Clinical Trials Group (ACTG). Read the study abstract; read NIAID’s news release about this research . . . 

Access Full Article

Clinical Trials

P1077BF: Breastfeeding Version of the PROMISE Study...

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

A5288: MULTIOCTAVE, Management Using the Latest Technologies...

The study is being done to: test a strategy of using a resistance test to choose anti-HIV drugs. Resistance tests look at the...

Read More

A5350: Effects of Visbiome Extra Strength on Gut Microbiome...

Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...

Read More

A5346: Sitagliptin for Reducing Inflammation and Immune...

The purpose of the study is to evaluate whether sitagliptin (Januvia is the brand name for sitagliptin)...

Read More

A5300/P2003: PHOENIx Feasibility Study

Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design

Read More